Apnar Pharma

Palatin Technologies is a biopharmaceutical research and development company with a focus on developing melanocortin-based therapeutics. Additionally, the company has a pipeline of product opportunities in development. The company s internal research and development capability, anchored by its proprietary MIDAS drug-discovery technology platform, is the core of its new product development program. Palatin s strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize its commercial potential. The company's flagship proprietary product is Bremelanotide, an intranasally administered melanocortin receptor agonist in development for the treatment of both male and female sexual dysfunction. Palatin Technologies has formed a strategic alliance with King Pharmaceuticals to jointly develop and commercialize Bremelanotide. Palatin Technologies maintains its corporate headquarters in Cranbury, N.J.

Experic LLC is a leading contract development and manufacturing organization (CDMO) and pharmaceutical supply services company based in Cranbury, NJ. They specialize in providing exceptional pharmaceutical development, clinical trial supply, and specialized commercial drug manufacturing services to small, midsize, and specialty pharmaceutical companies. With a team of industry experts and a state-of-the-art facility, Experic offers personalized attention, customized solutions, and unparalleled knowledge and expertise to support every phase of a product's life cycle. From conception to clinical and commercial scale, Experic manages global delivery of high-quality products, including tablets, capsules, and low dose dry powder inhalation. They prioritize timely access to expert resources, expedite clinical trial supplies, and advance commercial drug manufacturing, making them a trusted partner for pharmaceutical companies seeking exceptional service and reliable solutions.Generated from the website

UroGen Pharma Ltd is a biotech company based in Princeton, NJ, dedicated to developing and commercializing innovative solutions for urothelial and specialty cancers. Their groundbreaking therapies and clinical pipeline aim to revolutionize the treatment of these cancers by maximizing the potential benefit of local delivery through their novel RTGel technology, offering transformative, nonsurgical approaches to patients. UroGen is at the forefront of a transformative shift in urothelial and specialty cancer treatment, moving away from invasive surgeries towards nonsurgical means. Their first commercial product, JELMYTO mitomycin for pyelocalyceal solution, is the first and only FDA-approved nonsurgical treatment of its kind, utilizing their RTGel technology. With a focus on fundamentally changing the treatment paradigm, UroGen is committed to providing noninvasive therapeutic options for some of the most devastating cancers.Generated from the website